Relmada Therapeutics (RLMD) Cash & Equivalents (2012 - 2026)

Relmada Therapeutics (RLMD) has reported Cash & Equivalents for 15 consecutive years, with $9.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 750.34% year-over-year to $9.8 million; the TTM figure through Mar 2026 stood at $9.8 million (up 750.34% YoY), while the FY2025 annual figure was $3.5 million, down 9.35% from the prior year.
• Cash & Equivalents improved to $9.8 million in Q1 2026 per RLMD's latest filing, from $3.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $44.9 million in Q1 2022 and bottomed at $1.1 million in Q1 2025.
• Historically, Cash & Equivalents has averaged $12.4 million across 5 years, with a median of $4.1 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 1081.23% — and 2024, when it slumped 95.38%.
• Relmada Therapeutics' Cash & Equivalents stood at $5.4 million in 2022, then retreated by 24.17% to $4.1 million in 2023, then fell by 5.73% to $3.9 million in 2024, then decreased by 9.35% to $3.5 million in 2025, then soared by 179.6% to $9.8 million in 2026.
• Business Quant data shows RLMD's Cash & Equivalents at $9.8 million in Q1 2026, $3.5 million in Q4 2025, and $1.4 million in Q3 2025.